

## Highlights of This Issue 2193

### SPECIAL FEATURES

#### CCR 20<sup>th</sup> Anniversary Commentary

- 2195** CCR 20<sup>th</sup> Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio  
Susan E. Bates, Robert W. Robey, and Richard L. Piekarz
- 2198** CCR 20<sup>th</sup> Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy  
Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

#### CCR Translations

- 2201** A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2  
Yanping Xiao and Gordon J. Freeman  
*See related article, p. 2359*
- 2204** Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"  
Lisa M. Rimsza  
*See related article, p. 2367*

#### Molecular Pathways

- 2207** Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells  
Hiba Ahmad Zahreddine and Katherine L.B. Borden

#### CCR Focus

- 2212** Quit Early, Quit Often  
Susan E. Bates
- 2213** Lung Cancer in the Era of Precision Medicine  
Katerina Politi and Roy S. Herbst
- 2221** EGFR: The Paradigm of an Oncogene-Driven Lung Cancer  
Gregory J. Riely and Helena A. Yu
- 2227** Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine  
 Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw

- 2236** Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics  
David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch
- 2244** Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?  
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin
- 2256** Immune Checkpoint Modulation for Non-Small Cell Lung Cancer  
Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

#### Special Report

- 2263** Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care  
Edward Abrahams, Margaret Foti, and Marcia A. Kean

#### CANCER THERAPY: CLINICAL

- 2268** Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer  
Shinichi Kageyama, Hiroaki Ikeda, Yoshihiro Miyahara, Naoko Imai, Mikiya Ishihara, Kanako Saito, Sahoko Sugino, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi, Naoki Inoue, Masashige Tanabe, Tomohide Kidokoro, Hirofumi Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, and Hiroshi Shiku
- 2278** Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma  
Ling Zhang, Richard A. Morgan, Joal D. Beane, Zhili Zheng, Mark E. Dudley, Sadik H. Kassim, Azam V. Nahvi, Lien T. Ngo, Richard M. Sherry, Gao Q. Phan, Marybeth S. Hughes, Udai S. Kammula, Steven A. Feldman, Mary Ann Toomey, Sid P. Kerkar, Nicholas P. Restifo, James C. Yang, and Steven A. Rosenberg

# Table of Contents

**2289 Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition**

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, and F. Stephen Hodi

**2297 The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation**

Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, and Ferry A.L.M. Eskens

**2305 Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial**

Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dizon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

## PERSONALIZED MEDICINE AND IMAGING

**2315 Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer**

Arun A. Azad, Stanislav V. Volik, Alexander W. Wyatt, Anne Haegert, Stephane Le Bihan, Robert H. Bell, Shawn A. Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov, Jack Youngren, Pamela Paris, George Thomas, Eric J. Small, Yuzhuo Wang, Martin E. Gleave, Colin C. Collins, and Kim N. Chi

## CANCER THERAPY: PRECLINICAL

**2325 Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms**

Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

**2338 Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation**

Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

**2348 Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL**

Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Sridhar Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Krivtsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

## BIOLOGY OF HUMAN TUMORS

**2359 Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein**

Murali Janakiram, Jordan M. Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohaegbulam, Ruihua Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang  
*See related commentary, p. 2201*

**2367 Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System**

Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett, Chris G. Harbron, J. Carl Barrett, Elizabeth A. Harrington, and Kenneth S. Thress  
*See related commentary, p. 2204*

**2379 Molecular Changes Associated with Acquired Resistance to Crizotinib in *ROS1*-Rearranged Non-Small Cell Lung Cancer**

Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

**2388 Expression of Hedgehog Pathway Mediator *GLI* Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects**

Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Eik Vettorazzi, Gabi Vohwinkel, Marianne Klokow, Roswitha Uibelesen, Patrick Ehm, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jücker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

**2399 miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma**

Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdi, Lugui Qiu, and Hong Chang

## CORRECTION

**2412 Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer**


 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# Table of Contents

## ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.



# Clinical Cancer Research

**21 (10)**

*Clin Cancer Res* 2015;21:2193-2412.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/21/10>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/10>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.